Omeros Reports Successful Primate Study of OncotoX-AML for Leukemia Treatment

Reuters02-17

Omeros Reports Successful Primate Study of OncotoX-AML for Leukemia Treatment

Omeros Corporation announced the successful completion of an initial nonhuman primate study evaluating its OncotoX-AML therapeutic platform for acute myeloid leukemia (AML). The study demonstrated a marked, selective, and reversible reduction in myeloid progenitor cells, with OncotoX-AML being well tolerated and showing no significant safety signals. In preclinical murine-human xenograft models, OncotoX-AML also showed superior efficacy compared to standard-of-care treatments. The results from these studies have already been presented, and Omeros plans to initiate IND-enabling studies to advance OncotoX-AML toward clinical trials, targeting a first-in-human trial in late 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omeros Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202602170845BIZWIRE_USPR_____20260217_BW464206) on February 17, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612724457?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-17 21:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612724457","market":"fut","top_or_hot":-1,"title":"Omeros Reports Successful Primate Study of OncotoX-AML for Leukemia Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Omeros Reports Successful Primate Study of OncotoX-AML for Leukemia Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Omeros Corporation announced the successful completion of an initial nonhuman primate study evaluating its OncotoX-AML therapeutic platform for acute myeloid leukemia (AML). The study demonstrated a marked, selective, and reversible reduction in myeloid progenitor cells, with OncotoX-AML being well tolerated and showing no significant safety signals. In preclinical murine-human xenograft models, OncotoX-AML also showed superior efficacy compared to standard-of-care treatments. The results from these studies have already been presented, and Omeros plans to initiate IND-enabling studies to advance OncotoX-AML toward clinical trials, targeting a first-in-human trial in late 2027.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omeros Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202602170845BIZWIRE_USPR_____20260217_BW464206) on February 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Omeros Reports Successful Primate Study of OncotoX-AML for Leukemia Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOmeros Reports Successful Primate Study of OncotoX-AML for Leukemia Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-17 21:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Omeros Reports Successful Primate Study of OncotoX-AML for Leukemia Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Omeros Corporation announced the successful completion of an initial nonhuman primate study evaluating its OncotoX-AML therapeutic platform for acute myeloid leukemia (AML). The study demonstrated a marked, selective, and reversible reduction in myeloid progenitor cells, with OncotoX-AML being well tolerated and showing no significant safety signals. In preclinical murine-human xenograft models, OncotoX-AML also showed superior efficacy compared to standard-of-care treatments. The results from these studies have already been presented, and Omeros plans to initiate IND-enabling studies to advance OncotoX-AML toward clinical trials, targeting a first-in-human trial in late 2027.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omeros Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202602170845BIZWIRE_USPR_____20260217_BW464206) on February 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OMER","symbol_name":"奥麦罗制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL3zNJkg:1","article_id":"2612724457","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612724457","pubTimestamp":1771335918,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Omeros Corporation announced the successful completion of an initial nonhuman primate study evaluating its OncotoX-AML therapeutic platform for acute myeloid leukemia . The study demonstrated a marked, selective, and reversible reduction in myeloid progenitor cells, with OncotoX-AML being well tolerated and showing no significant safety signals. In preclinical murine-human xenograft models, OncotoX-AML also showed superior efficacy compared to standard-of-care treatments. The results from these studies have already been presented, and Omeros plans to initiate IND-enabling studies to advance OncotoX-AML toward clinical trials, targeting a first-in-human trial in late 2027.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OMER":"奥麦罗制药","BK4007":"制药"},"translate_title":"Omeros报告OncotoX-AML治疗白血病的灵长类动物研究取得成功","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMER":0.9},"content_text":"Omeros Reports Successful Primate Study of OncotoX-AML for Leukemia Treatment\n    \n\n        Omeros Corporation announced the successful completion of an initial nonhuman primate study evaluating its OncotoX-AML therapeutic platform for acute myeloid leukemia (AML). The study demonstrated a marked, selective, and reversible reduction in myeloid progenitor cells, with OncotoX-AML being well tolerated and showing no significant safety signals. In preclinical murine-human xenograft models, OncotoX-AML also showed superior efficacy compared to standard-of-care treatments. The results from these studies have already been presented, and Omeros plans to initiate IND-enabling studies to advance OncotoX-AML toward clinical trials, targeting a first-in-human trial in late 2027.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omeros Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202602170845BIZWIRE_USPR_____20260217_BW464206) on February 17, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612724457","isCrawlerRequest":true}